Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: A method of predicting risk of an aggressive or a recurrent prostate cancer in an individual, the method comprising a step of assaying a biological sample from the individual for expression of at least two genes, or proteins encoded by said genes, selected from TTC21B, MCM3, MTUS1, FOXM1, CUL4A, GPC1, PCNA, IRF7, BRIP1, ULKI, and SPAG5, wherein when a combination of a normalised expression value of the at least two genes, or proteins encoded by said genes, is modified relative to a combination of a normalised expression reference value of the at least two genes, or proteins encoded by said, in a biological sample from a subject with non-aggressive or non-recurrent prostate cancer, the individual is predicted to have an increased risk of having an aggressive or a recurrent prostate cancer.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: A mechanism is provided for storing multiple bits in a domain wall nanowire magnetic junction device. The multiple bits are encoded based on a resistance of the domain wall nanowire magnetic junction device using a single domain wall. The single domain wall is shifted to change the resistance of the domain wall nanowire magnetic junction device to encode a selected bit. The resistance is checked to ensure that it corresponds to a preselected resistance for the selected bit. Responsive to the resistance corresponding to the preselected resistance for the selected bit, he selected bit is stored. Responsive to the resistance not being the preselected resistance for the selected bit, the single domain wall is shifted until the resistance corresponds to the preselected resistance.

Abstract: A mechanism is provided for storing multiple bits in a domain wall nanowire magnetic junction device. The multiple bits are encoded based on a resistance of the domain wall nanowire magnetic junction device using a single domain wall. The single domain wall is shifted to change the resistance of the domain wall nanowire magnetic junction device to encode a selected bit. The resistance is checked to ensure that it corresponds to a preselected resistance for the selected bit. Responsive to the resistance corresponding to the preselected resistance for the selected bit, the selected bit is stored. Responsive to the resistance not being the preselected resistance for the selected bit, the single domain wall is shifted until the resistance corresponds to the preselected resistance.

Abstract: A method for software performance analysis and debugging in a multi-tenant database network system is provided. In at least one embodiment, sampling is achieved using configuration files of each server cluster. Knowledge of the host names of each server in the cluster enables a profiler to target a single server for each sample, thereby facilitating a round-robin sample across a clustered server environment such that a CPU's load and processing cost associated to sampling is fairly and uniformly distributed across all servers in the cluster. As a result, in at least one embodiment of the analysis and debugging tool each sample is a complete stack trace dump of each thread running on the application server at that moment in time.

Abstract: A method for software debugging in a multi-tenant database network system is provided. When an exception occurs the stack frames in temporary working memory are dumped into long term memory for later analysis. A stack trace is performed from which performance information may be derived, which may aid in discovering the cause of the exception.

Abstract: A mechanism is provided for storing multiple bits in a domain wall nanowire magnetic junction device. The multiple bits are encoded based on a resistance of the domain wall nanowire magnetic junction device using a single domain wall. The single domain wall is shifted to change the resistance of the domain wall nanowire magnetic junction device to encode a selected bit. The resistance is checked to ensure that it corresponds to a preselected resistance for the selected bit. Responsive to the resistance corresponding to the preselected resistance for the selected bit, he selected bit is stored. Responsive to the resistance not being the preselected resistance for the selected bit, the single domain wall is shifted until the resistance corresponds to the preselected resistance.

Abstract: A mechanism is provided for storing multiple bits in a domain wall nanowire magnetic junction device. The multiple bits are encoded based on a resistance of the domain wall nanowire magnetic junction device using a single domain wall. The single domain wall is shifted to change the resistance of the domain wall nanowire magnetic junction device to encode a selected bit. The resistance is checked to ensure that it corresponds to a preselected resistance for the selected bit. Responsive to the resistance corresponding to the preselected resistance for the selected bit, he selected bit is stored. Responsive to the resistance not being the preselected resistance for the selected bit, the single domain wall is shifted until the resistance corresponds to the preselected resistance.

Abstract: A method for software debugging in a multi-tenant database network system is provided. When an exception occurs the stack frames in temporary working memory are dumped into long term memory for later analysis. A stack trace is performed from which performance information may be derived, which may aid in discovering the cause of the exception.

Abstract: The present invention relates generally to a method for determining the level of expression of one or more candidate objects of interest in a biological sample. In particular, the present invention relates to a method for determining the level of expression of one or more candidate objects of interest using image analysis. More specifically, the present invention relates to a method and a system for determining the level of expression of one or more candidate objects of interest using an automated (computer-aided) image analysis system.

Abstract: A method for software performance analysis and debugging in a multi-tenant database network system is provided. In at least one embodiment, sampling is achieved using configuration files of each server cluster. Knowledge of the host names of each server in the cluster enables a profiler to target a single server for each sample, thereby facilitating a round-robin sample across a clustered server environment such that a CPU's load and processing cost associated to sampling is fairly and uniformly distributed across all servers in the cluster. As a result, in at least one embodiment of the analysis and debugging tool each sample is a complete stack trace dump of each thread running on the application server at that moment in time.

Abstract: The present invention relates generally to a method for determining the level of expression of one or more candidate objects of interest in a biological sample. In particular, the present invention relates to a method for determining the level of expression of one or more candidate objects of interest using image analysis. More specifically, the present invention relates to a method and a system for determining the level of expression of one or more candidate objects of interest using an automated (computer-aided) image analysis system.

Abstract: A method and system for providing attribute verification (330) consistent with the invention includes obtaining the attributes (320) of the item prior to placing the item in a delivery system (350), verifying correctness of the attributes (320), and transmitting an indication of the correctness of the attributes to a delivery system operator over a communications system (340).

Abstract: An angle grinder is provided including a rotating handle configuration allowing the handle of the angle grinder to be locked in different positions relative to the angle grinder housing. A switch mounting configuration is provided for simplifying the assembly of the switch device. A gear wheel lock mechanism is also provided to allow the grinding wheel spindle to be prevented from rotating during removal or installation of a grinding wheel on the spindle. A gear case cooling and air bleed arrangement are also provided.

Abstract: A method of diagnosing melanoma and/or monitoring melanoma progression, in particular for determining whether the melanoma is likely to have metastatic capabilities, in a subject includes the steps of in a test sample determining the methylation status of FABP5 wherein methylation of the gene indicates a positive diagnosis of melanoma and/or increased methylation of the gene indicates the progression of melanoma. Methods of monitoring melanoma progression may also incorporate measuring the expression levels of FABP5, with low levels of expression indicating a positive diagnosis of melanoma and/or lower levels of expression being indicative of progression of melanoma. Methods of treating melanoma in a subject comprise administering a therapeutically effective amount of a DNA methyltransferase inhibitor or a histone deacetylase inhibitor to the subject such that expression of FABP5 is increased.